Rep. Gilbert Ray Cisneros Jr. (D-CA) Sells AtriCure (ATRC) Stock

Democratic Representative Gilbert Ray Cisneros Jr. reported selling a stake in AtriCure, Inc. (NasdaqGM: ATRC) in a transaction executed on September 29, 2026. The trade was disclosed in a periodic transaction report filed under the STOCK Act on October 12, 2026.

Inside Representative Cisneros's AtriCure Trade

The Democratic lawmaker from California's 31st district reported selling shares valued between $1,001 and $15,000. Congressional disclosure rules require members to report stock trades within specified windows, using broad dollar ranges rather than exact share quantities or prices. AtriCure closed at $58.05 on the day the transaction took place.

Other Institutional Activity in AtriCure

Large financial institutions adjusted their positions in AtriCure during the second quarter. Blackrock Inc. grew its holdings by 431,769 shares, ending with 4,474,548 shares worth about $250,887,904. Wellington Management Group, LLP grew its holdings by 112,980 shares, ending with 3,495,603 shares worth about $195,998,459. Vanguard Portfolio Management LLC grew its holdings by 424,581 shares, ending with 3,127,195 shares worth about $175,341,822. Hood River Capital Management LLC reduced its holdings by 212,309 shares, ending with 2,905,299 shares worth about $162,900,114. Alliancebernstein L.P. reduced its holdings by 490,452 shares, ending with 2,768,365 shares worth about $155,222,224.

AtriCure, Inc. Stock Down 0.6%

AtriCure shares recently traded around $57.45, down about 1.0% since the September trade date. The stock has experienced solid momentum, trading above its 50-day moving average of $52.17 and well above its 200-day moving average of $37.01. The medical device maker carries a market capitalization of roughly $2.85 billion.

Recent Earnings

AtriCure generated $569,622,016 in trailing-twelve-month revenue with earnings of $0.21 per share. The company reported a 12.8% year-over-year increase in revenue, alongside a net profit margin of 1.9% and a return on equity of 2.2%. The company's next quarterly financial update is slated for November 3, 2026.

Insider Buying and Selling at AtriCure, Inc.

Company insiders executed several sales prior to the representative's trade. Chief Technology Officer Salvatore Privitera sold 7,763 shares on September 2, 2026, at an average price of $52.50 for a total value of $407,558. Mr. Privitera later sold 3,657 shares on September 8, 2026, at $55.00 per share, totaling $201,135. Director Regina E Groves sold 5,313 shares on September 11, 2026, at $54.22 per share, worth $288,071. Mr. Privitera returned to sell another 4,519 shares on September 23, 2026, at $60.00 per share, totaling $271,140.

Analysts Set New Price Targets

Wall Street firms updated their views on AtriCure ahead of the autumn months. UBS maintained a Buy rating on July 28, 2026, adjusting its price target from $55.00 to $50.00. BTIG maintained a Buy rating on August 24, 2026, raising its target from $45.00 to $55.00. Piper Sandler maintained an Overweight rating on August 27, 2026, lifting its target from $50.00 to $60.00. Needham maintained a Buy rating on September 2, 2026, boosting its target from $45.00 to $64.00. Overall, the stock holds a consensus buy rating among analysts, with a mean price target of $55.78 across nine analyst opinions.

About AtriCure

Headquartered in Mason, Ohio, AtriCure designs and manufactures medical devices targeted at surgical ablation of cardiac tissue and the management of atrial fibrillation. The company's specialized instruments are utilized by medical centers across the United States and international markets to treat complex heart conditions and block peripheral nerve pain.

Bottom Line

Investors tracking congressional disclosures and healthcare sector equities will look toward AtriCure's upcoming earnings release on November 3, 2026, for further operational updates. Congressional stock disclosures offer a window into personal portfolio adjustments made by lawmakers, though they do not signal broader corporate or market trends.